Effects of combined use of atorvastatin and losartan in treating patients with diabetic nephropathy | Zendy

Chao Ding | Zendy; Xiaohua Hu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effects of combined use of atorvastatin and losartan in treating patients with diabetic nephropathy

Author(s) -

Chao Ding,

Xiaohua Hu

Publication year - 2018

Publication title -

european journal of inflammation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.219

H-Index - 20

eISSN - 2058-7392

pISSN - 1721-727X

DOI - 10.1177/2058739218796707

Subject(s) - atorvastatin , medicine , losartan , diabetic nephropathy , triglyceride , endocrinology , interleukin 6 , renal function , nephropathy , diabetes mellitus , gastroenterology , high density lipoprotein , c reactive protein , lipoprotein , blood lipids , cholesterol , angiotensin ii , inflammation , blood pressure

This study is to investigate the effect of atorvastatin combined with losartan on inflammatory factors, vascular endothelial function, and cardiovascular events in patients with diabetic nephropathy. A total of 128 patients with diabetic nephropathy treated in our hospital from January 2014 to December 2015 were selected as the study subjects, and 64 cases were randomly divided into observation group and 64 cases in the control group. The control group was treated with losartan on the basis of routine treatment, and the observation group was treated with atorvastatin on the basis of the control group. The blood lipid, inflammatory factors, changes in vascular endothelial function and cardiovascular events were compared between the two groups. The levels of total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) were not significantly different between the two groups before treatment ( P > 0.05); after treatment, the levels of TC, TG, and LDL-C in the observation group were significantly lower than those of the control group, and the level of HDL-C was significantly higher than that of the control group ( P 0.05); after treatment, the levels of hs-CRP, TNF-α, and IL-6 in the observation group were significantly lower than those of the control group ( P 0.05). After treatment, the level of ET-1 in the observation group was significantly lower than that of the control group ( P < 0.05), and the level of NO was significantly higher than that of the control group ( P < 0.05). After treatment, all patients were followed up for 2 years, and the incidence of secondary cardiovascular events in the observation group was 12.50% (8/64), which was significantly lower than 29.69% (19/64) of the control group ( P < 0.05). Combination of atorvastatin and losartan can significantly improve the levels of blood lipid, inflammatory factors, and vascular endothelial function in patients with diabetic nephropathy and can effectively reduce the incidence of cardiovascular events.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research